Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7912475 | 1.00 | ESR1 (0.62) | ESR1ESR2MTNR1AMTNR1BMEN1 | |
| SCHEMBL5606420 | 1.00 | ESR1 (0.62) | ESR1ESR2MTNR1AMTNR1BMEN1 | |
| SCHEMBL8393141 | 0.88 | ESR1 (0.82) | ESR1ESR2MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL3988719 | 0.88 | ESR1 (0.82) | ESR1ESR2MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL10850323 | 0.88 | ESR1 (0.59) | ESR1ESR2MTNR1AMTNR1BMEN1 | |
| SCHEMBL8393139 | 0.88 | ESR1 (0.82) | ESR1ESR2MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL9622832 | 0.88 | ESR1 (0.82) | ESR1ESR2MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL3988713 | 0.88 | ESR1 (0.82) | ESR1ESR2MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL30404084 | 0.84 | PTGS1 (0.57) | ESR1ESR2MTNR1AMTNR1BPTGS1 | |
| SCHEMBL14970299 | 0.84 | PTGS1 (0.68) | ESR1ESR2MEN1KMT2APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0290012-A1 | TGF-B2 and novel compositions having anti-neoplastic activity | ONCOGEN (US) | 1988-11-09 | — | — | EP | claimed |
| EP-4663633-A1 | COMBINED PHARMACEUTICAL COMPOSITION OF SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024165068-A1 | COMBINED PHARMACEUTICAL COMPOSITION OF SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-08-15 | — | — | WO | disclosed |
| WO-2023035614-A1 | DRUG COMBINATION CONTAINING PI3Kα INHIBITOR | 上海海和药物研究开发股份有限公司 | 2023-03-16 | — | — | WO | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| CN-110294788-A | New compound and application thereof | 冰洲石生物科技公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-108495618-B | Novel compounds and uses thereof | 冰洲石生物科技公司 | 2019-08-16 | — | — | CN | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-2459727-A2 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123155-A1 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2011012632-A2 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2011-02-03 | — | — | WO | disclosed |
| EP-1754709-A1 | Process for preparing vinylphosphates | DSM IP Assets B.V. (NL) | 2007-02-21 | — | — | EP | disclosed |
| US-6759498-B2 | Continuous anionic polymerization of mixtures comprising aromatic olefins, solvents and organolithium compounds, to form polymers having narrow molecular weight distribution and heat resistance used as packaging containers | ASAHI KADEI KABUSHIKI KAISHA (JP) | 2004-07-06 | — | — | US | disclosed |
| US-20030181610-A1 | Process for producing styrene resin reduced in content of low-molecular ingredient | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-09-25 | — | — | US | disclosed |
| US-6608212-B1 | Palladium catalyzed coupling of a vinylphosphate and aryl-metal halide; preparation of such as 1-(4-(2-(pyrrolidin-n-yl)-ethoxy)phenyl)-6-methoxy-3,4-dihydronaphthalene | PFIZER, INC. | 2003-08-19 | — | — | US | disclosed |
| EP-0290012-A1 | TGF-B2 and novel compositions having anti-neoplastic activity | ONCOGEN (US) | 1988-11-09 | — | — | EP | disclosed |
| US-4339595-A | Hexa(meta-,para-carboxyphenyl)benzene compounds | STANDARD OIL COMPANY (INDIANA) (US) | 1982-07-13 | — | — | US | disclosed |
| EP-0019377-A1 | 1-Hydrocarbyloxyphenyl-1,2-diphenylalkene derivatives, their manufacture and a pharmaceutical composition containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123155-A1 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | HDHD5, PAH, GRHPR | ESR1 4055/4885ESR2 4489/4885MTNR1A 2503/4885 |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885MTNR1A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.